Form 4: Artiva CFO's Routine Stock Holdings Update
Insider Transaction Report
Artiva Biotherapeutics' CFO, Neha Krishnamohan, reported changes in her beneficial ownership due to tax withholdings from vested restricted stock units.
Summary
- Neha Krishnamohan, Chief Financial Officer of Artiva Biotherapeutics, Inc. (ARTV), reported changes in her beneficial ownership of common stock.
- On May 15, 2025, 1,341 shares were disposed of at $2.13 per share.
- On August 15, 2025, an additional 5,813 shares were disposed of at $2.75 per share.
- These dispositions represent shares withheld by Artiva Biotherapeutics to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
- Following these transactions, Ms. Krishnamohan directly owns 102,846 shares of common stock.
Sentiment
Score: 5
Explanation: The filing reports routine tax-related share dispositions by an insider, which is a neutral event and does not indicate a change in company fundamentals or insider sentiment.
Future Outlook
No forward-looking statements or guidance are provided in this Form 4 filing, as it pertains solely to changes in beneficial ownership.
Industry Context
This Form 4 filing is a routine disclosure of insider stock transactions, specifically related to tax withholdings from vested equity awards. Such transactions are common across all publicly traded companies as part of executive compensation plans and do not typically reflect strategic shifts or operational performance.
Stakeholder Impact
- Shareholders: Minimal impact, as these are routine tax-related transactions and do not indicate a discretionary sale by the insider.
- Employees: No direct impact beyond the reporting person's compensation structure.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Transaction date for the disposition of 1,341 common shares. |
| 08/15/2025 | Transaction date for the disposition of 5,813 common shares. |
| 08/18/2025 | Signature date of the reporting person, Neha Krishnamohan. |
Recommendation
holdThis Form 4 reports routine share dispositions by the CFO to cover tax obligations from vested restricted stock units. It does not reflect a discretionary sale or provide new information about the company's operational performance or strategic direction, thus it does not warrant a change in investment recommendation based solely on this filing.
Keywords
Artiva Biotherapeutics, ARTV, Form 4, Insider Transaction, Stock Ownership, CFO, Neha Krishnamohan, Restricted Stock Units, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.